Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) generates frequent news flow as a clinical-stage biotechnology company developing neflamapimod for dementia with Lewy bodies (DLB) and other age-related brain disorders. The company’s updates often center on clinical data releases, regulatory interactions, and corporate developments tied to its lead program.
Investors following CRVO news can expect detailed announcements on results from the Phase 2b RewinD-LB trial in DLB, including subgroup analyses, biomarker findings, and longer-term extension data. CervoMed has reported that neflamapimod treatment in DLB was associated with effects on the Clinical Dementia Rating – Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), and plasma biomarkers such as glial fibrillary acidic protein (GFAP), Aβ42/40 ratio, and neurofilament light. These news items provide insight into how the company interprets clinical and biomarker outcomes in its target population, particularly patients with a low likelihood of Alzheimer’s disease co-pathology.
CervoMed’s news flow also includes regulatory milestones, such as written feedback from the U.S. Food and Drug Administration aligning on key aspects of the planned Phase 3 trial design in DLB. Articles may describe planned trial parameters, enrichment strategies using plasma ptau181, and the role of CDR-SB as the primary endpoint. Additional coverage highlights participation in scientific conferences, presentations at dementia and neurology meetings, and dissemination of new analyses of trial data.
Beyond clinical and regulatory updates, CRVO news features quarterly financial results, grant funding details, and changes to the company’s leadership and board composition. Announcements of executive appointments, board expansions, and investor conference participation help contextualize CervoMed’s preparation for late-stage development and potential commercialization of neflamapimod. This news page aggregates these items so readers can track how scientific results, regulatory feedback, and corporate actions evolve over time.
CervoMed Inc. (NASDAQ: CRVO) announced positive results from the Extension phase of their Phase 2b RewinD-LB study of neflamapimod for treating dementia with Lewy bodies (DLB). The study showed that neflamapimod, when administered with New Capsules achieving target plasma concentrations, significantly slowed clinical progression compared to controls.
Key findings include:
- Improvement in Clinical Dementia Rating Sum of Boxes (CDR-SB) with New Capsules vs Old Capsules (p<0.001) and vs placebo (p=0.003)
- Mean improvement of 0.73 points with New Capsules compared to Old Capsules
- 40% lower rate of clinical worsening in New Capsule recipients
- Improved outcomes in Alzheimer's Disease Cooperative Study (ADCS-CGIC)
- Reduced incidence of falls (4% vs 15.2%) with New Capsules
The results will be presented at the AD/PD™ 2025 conference on April 5, 2025, demonstrating proof-of-concept for neflamapimod as a DLB treatment.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced an upcoming oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AP/PD™) in Vienna, Austria on April 5, 2025.
The presentation will focus on detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). The presentation will be delivered by CEO John Alam, MD, and Stephen Gomperts, MD, PhD, from Harvard Medical School and Massachusetts General Hospital.
CervoMed (NASDAQ: CRVO) has reported its Q4 and full-year 2024 financial results, highlighting positive 16-week results from the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). The trial showed significant improvements in the primary outcome measure.
Financial highlights include:
- Cash position of $38.9 million as of December 31, 2024 (up from $7.8M in 2023)
- Grant revenue of $9.7 million for 2024 (up from $7.1M in 2023)
- R&D expenses increased to $18.8 million (from $8.4M in 2023)
- Net loss of $16.3 million for 2024
The company plans to initiate a Phase 3 trial in mid-2026 and expects to report 32-week extension phase results in H2 2025. Current cash runway extends into mid-2026.
CervoMed (NASDAQ: CRVO) has announced positive results from the 16-week extension phase of its Phase 2b RewinD-LB study for neflamapimod in treating dementia with Lewy bodies (DLB). The new batch of drug capsules showed significant improvements compared to both old capsules and placebo:
Key findings include:
- Improved Clinical Dementia Rating Sum of Boxes (CDR-SB) scores (p<0.001 vs. old capsules; p=0.003 vs. placebo)
- Better performance on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (p=0.035)
- Lower incidence of falls (7.4% vs. 14.5% for old capsules)
- Higher plasma drug concentrations (5.1 vs. 4.0 ng/mL, p=0.03)
The study involved 149 participants, with 94 receiving the new capsules and 55 receiving old capsules. The results suggest neflamapimod's potential to fundamentally change DLB treatment, particularly significant as no FDA-approved drugs currently exist for DLB management in the U.S.
CervoMed (NASDAQ: CRVO) provided an update on its neflamapimod development program for dementia with Lewy bodies (DLB) at the 8th International Lewy Body Dementia Conference. The Phase 2b RewinD-LB trial's blinded portion showed no significant differences between neflamapimod 40mg (three times daily) and placebo groups.
The company identified that lower-than-expected bioavailability may be related to the age of the drug batch used during the double-blind phase. However, newer capsules tested in Q4 2024 achieved targeted plasma concentrations in both a food effect study and in 13 participants during the open-label extension (OLE) phase.
Topline data from the first 16 weeks of the OLE phase, including participants receiving the newer capsules, is expected in Q1 2025. This data will include various efficacy endpoints and pharmacokinetic data, which will guide future development decisions.
CervoMed (NASDAQ: CRVO) has announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference (ILBDC) in Amsterdam on January 31, 2025. The study focuses on neflamapimod treatment for dementia with Lewy bodies (DLB).
The presentation, titled 'Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB),' will be delivered by Dr. John Alam, CEO and Co-Principal Investigator of the study, during Symposium VIII-Therapy at 13:30 CET / 7:30 ET. The initial topline results were previously disclosed on December 10, 2024.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, has granted equity awards to two new employees. The company awarded options to purchase a total of 14,753 shares of common stock, with an exercise price of $11.91 per share, matching the closing price on December 6, 2024. These options will vest over three years in 36 equal monthly installments, contingent on continued employment. The grants were approved by the Compensation Committee as inducement awards under Nasdaq Listing Rule 5635(c)(4).
CervoMed (NASDAQ: CRVO) announced disappointing topline data from its RewinD-LB Phase 2b clinical trial evaluating neflamapimod for treating dementia with Lewy bodies (DLB). The trial failed to meet statistical significance for its primary endpoint (CDR-SB) and key secondary endpoints. Target plasma drug concentrations were not achieved during the trial's double-blind phase, potentially affecting the results.
While the drug showed favorable safety and tolerability with no new safety concerns, CervoMed is pausing preparations for the planned Phase 3 trial until completing a thorough analysis. The company expects the full double-blind phase data in January 2025 and open-label extension data in late Q2 2025.
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD). The designation applies to therapies for rare diseases affecting fewer than 200,000 people in the US and provides benefits including tax credits, development assistance, and seven years of marketing exclusivity. The company is preparing for a Phase 3 trial in dementia with Lewy bodies (DLB) in mid-2025 and expects topline data from the RewinD-LB Phase 2b trial in December 2024.
CervoMed (NASDAQ: CRVO) announced two key senior leadership appointments to advance the development of neflamapimod. Dr. Claudia Ordonez joined as Senior Vice President, Medical Science, bringing expertise from previous roles at Vertex and Biogen. Dr. Mark De Rosch was appointed Senior Vice President, Regulatory and Government Affairs and Program Management, contributing over 30 years of experience in regulatory and CMC functions. The company expects topline data from the RewinD-LB study in December 2024 and plans Phase 3 initiation in mid-2025 for dementia with Lewy Bodies treatment. The company also granted stock options to three new employees, including 32,000 shares to Dr. De Rosch at $12.53 per share.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
